A reassessment of triazolam

Anthony Kales, Alexandros Vgontzas, Edward Bixler

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Concern over the safety of triazolam is reflected in the actions taken against the drug world-wide by many drug regulatory agencies, ranging from restrictions in duration of use and dosage to banning of the drug. There is extensive scientific literature documenting that triazolam produces frequent and severe psychiatric adverse events: during drug administration these include memory impairment/amnesia and other cognitive impairments and daytime anxiety states and early morning insomnia; following drug withdrawal there can be a marked worsening of sleep (rebound insomnia). It is difficult to improve triazolam's benefit-to-risk ratio either by lowering the dose or by short and intermittent use. The 0.5 mg and 1.0 mg doses of triazolam are effective, but produce severe psychiatric adverse events while the 0.25 mg dose has limited efficacy while still being associated with frequent adverse events. Moreover, many of triazolam's adverse events are associated with the first (or first several) doses used, and rebound insomnia often occurs on withdrawal even after only one night of use.

Original languageEnglish (US)
Pages (from-to)7-27
Number of pages21
JournalInternational Journal of Risk and Safety in Medicine
Volume9
Issue number1
StatePublished - 1996

Fingerprint

Triazolam
Sleep Initiation and Maintenance Disorders
Pharmaceutical Preparations
Psychiatry
Data storage equipment
Literature
Amnesia
Drug-Related Side Effects and Adverse Reactions
Sleep
Anxiety
Odds Ratio
Safety

All Science Journal Classification (ASJC) codes

  • Safety, Risk, Reliability and Quality
  • Public Health, Environmental and Occupational Health

Cite this

Kales, Anthony ; Vgontzas, Alexandros ; Bixler, Edward. / A reassessment of triazolam. In: International Journal of Risk and Safety in Medicine. 1996 ; Vol. 9, No. 1. pp. 7-27.
@article{21dfd15b7d2943ef95f39cfd0053975e,
title = "A reassessment of triazolam",
abstract = "Concern over the safety of triazolam is reflected in the actions taken against the drug world-wide by many drug regulatory agencies, ranging from restrictions in duration of use and dosage to banning of the drug. There is extensive scientific literature documenting that triazolam produces frequent and severe psychiatric adverse events: during drug administration these include memory impairment/amnesia and other cognitive impairments and daytime anxiety states and early morning insomnia; following drug withdrawal there can be a marked worsening of sleep (rebound insomnia). It is difficult to improve triazolam's benefit-to-risk ratio either by lowering the dose or by short and intermittent use. The 0.5 mg and 1.0 mg doses of triazolam are effective, but produce severe psychiatric adverse events while the 0.25 mg dose has limited efficacy while still being associated with frequent adverse events. Moreover, many of triazolam's adverse events are associated with the first (or first several) doses used, and rebound insomnia often occurs on withdrawal even after only one night of use.",
author = "Anthony Kales and Alexandros Vgontzas and Edward Bixler",
year = "1996",
language = "English (US)",
volume = "9",
pages = "7--27",
journal = "International Journal of Risk and Safety in Medicine",
issn = "0924-6479",
publisher = "IOS Press",
number = "1",

}

A reassessment of triazolam. / Kales, Anthony; Vgontzas, Alexandros; Bixler, Edward.

In: International Journal of Risk and Safety in Medicine, Vol. 9, No. 1, 1996, p. 7-27.

Research output: Contribution to journalReview article

TY - JOUR

T1 - A reassessment of triazolam

AU - Kales, Anthony

AU - Vgontzas, Alexandros

AU - Bixler, Edward

PY - 1996

Y1 - 1996

N2 - Concern over the safety of triazolam is reflected in the actions taken against the drug world-wide by many drug regulatory agencies, ranging from restrictions in duration of use and dosage to banning of the drug. There is extensive scientific literature documenting that triazolam produces frequent and severe psychiatric adverse events: during drug administration these include memory impairment/amnesia and other cognitive impairments and daytime anxiety states and early morning insomnia; following drug withdrawal there can be a marked worsening of sleep (rebound insomnia). It is difficult to improve triazolam's benefit-to-risk ratio either by lowering the dose or by short and intermittent use. The 0.5 mg and 1.0 mg doses of triazolam are effective, but produce severe psychiatric adverse events while the 0.25 mg dose has limited efficacy while still being associated with frequent adverse events. Moreover, many of triazolam's adverse events are associated with the first (or first several) doses used, and rebound insomnia often occurs on withdrawal even after only one night of use.

AB - Concern over the safety of triazolam is reflected in the actions taken against the drug world-wide by many drug regulatory agencies, ranging from restrictions in duration of use and dosage to banning of the drug. There is extensive scientific literature documenting that triazolam produces frequent and severe psychiatric adverse events: during drug administration these include memory impairment/amnesia and other cognitive impairments and daytime anxiety states and early morning insomnia; following drug withdrawal there can be a marked worsening of sleep (rebound insomnia). It is difficult to improve triazolam's benefit-to-risk ratio either by lowering the dose or by short and intermittent use. The 0.5 mg and 1.0 mg doses of triazolam are effective, but produce severe psychiatric adverse events while the 0.25 mg dose has limited efficacy while still being associated with frequent adverse events. Moreover, many of triazolam's adverse events are associated with the first (or first several) doses used, and rebound insomnia often occurs on withdrawal even after only one night of use.

UR - http://www.scopus.com/inward/record.url?scp=0030498240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030498240&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:0030498240

VL - 9

SP - 7

EP - 27

JO - International Journal of Risk and Safety in Medicine

JF - International Journal of Risk and Safety in Medicine

SN - 0924-6479

IS - 1

ER -